That growing obesity problem--What to do?

Semaglutide plus lifestyle changes moved 40.4% of children below the obesity threshold at 68 weeks in the phase 3 STEP Young trial.

Semaglutide cut testosterone by half in early trial data — but one patient's rapid weight loss revealed a real risk. Our experts weigh the promise of GLP-1 therapy against how fast is too fast for teens.

Which labs actually change management? Our experts debate fasting insulin versus A1c, explain why total testosterone can mislead, and share the LH-to-FSH trick that helps settle ambiguous cases.

Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.

Ovarian ultrasound doesn't apply to teens. Our experts walk through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.

A global Lancet consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.

FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.

Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.